Patient-Derived Xenografts to Reduce Cancer Health Disparities
Recruiting · NCT04410302 · Observational (researchers observe without assigning treatment) · Lead sponsor: University of California, Davis
View the official record on ClinicalTrials.gov →Interventions studied
Biospecimen Collection
What this trial is about
This trial establishes patient-derived cancer xenografts in addressing cancer health and treatment disparities that disproportionately affect racial/ethnic minorities. Understanding the genetic and response differences among racial/ethnic minorities may help researchers enhance the precision of therapeutic treatments.
Who can take part
Age range
21 Years to 100 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Patient receiving treatment for the above 4 cancers (bladder cancer, lung cancer, gastric/stomach cancer, and liver cancer)
- Signed informed consent that will be put on file
Exclusion criteria
- No informed consent obtained
- Specimen unacceptable/degraded/etc.
- Individuals who are not yet adults (infants, children, teenagers)
- Pregnant women
- Prisoners
- Adults unable to consent
Where it is running
2 locations listed across 1 US state.
- UC Irvine Health/Chao Family Comprehensive Cancer Center - Orange, California, United States
- University of California Davis Comprehensive Cancer Center - Sacramento, California, United States